Venable Represents Dechra in Acquisition of Worldwide Rights to Osurnia Product Portfolio

1 min

Venable represented Dechra Pharmaceuticals PLC, an international veterinary pharmaceuticals and related products business, in the acquisition of the worldwide rights to the Osurnia product portfolio from Elanco Animal Health Incorporated for $135 million. The addition of Osurnia to the Dechra dermatology portfolio will significantly enhance its presence in this key therapeutic area and complete its otitis externa service offering to veterinarians.

Osurnia is a long-acting treatment for otitis externa (inflammation of the outer ear) in dogs. Dechra is acquiring the worldwide marketing rights; the rights to the intellectual property; the marketing authorizations and associated regulatory documentation; supply contracts with third parties in relation to the raw material and manufacture of the finished product; and some existing inventory of the product.

Completion of the acquisition is expected before the end of June 2020, following the satisfaction of a number of conditions precedent.

Venable handled the U.S. aspect of the deal. The team of attorneys included Karen Hermann, Jim Nelson, Caitlyn Bingaman, Becca Chappell, Cameron Cole, Lisa Jose Fales, Paul Feinstein, Nicole Goodwin, Ryan Kashfian, Marjorie Norman, Scott Rissmiller, Friedemann Thomma, Andrew Weinstein, Lauren Williams, and Shannyn Yates.